Clinical biology of the pituitary adenoma
S Melmed, UB Kaiser, MB Lopes, J Bertherat… - Endocrine …, 2022 - academic.oup.com
All endocrine glands are susceptible to neoplastic growth, yet the health consequences of
these neoplasms differ between endocrine tissues. Pituitary neoplasms are highly prevalent …
these neoplasms differ between endocrine tissues. Pituitary neoplasms are highly prevalent …
Aggressive pituitary tumours and pituitary carcinomas
Although usually benign, anterior pituitary tumours occasionally exhibit aggressive
behaviour, with invasion of surrounding tissues, rapid growth, resistance to conventional …
behaviour, with invasion of surrounding tissues, rapid growth, resistance to conventional …
Biological and therapeutic implications of the tumor microenvironment in pituitary adenomas
Pituitary adenomas (PAs) are neoplasms derived from the endocrine cells of the anterior
pituitary gland. Most frequently, they are benign tumors, but may sometimes display an …
pituitary gland. Most frequently, they are benign tumors, but may sometimes display an …
Immunotherapy in aggressive pituitary tumors and carcinomas: a systematic review
MD Ilie, A Vasiljevic, E Jouanneau… - Endocrine-related …, 2022 - erc.bioscientifica.com
Once temozolomide has failed, there is no recommended treatment option for pituitary
carcinomas and aggressive pituitary tumors. Immune-checkpoint inhibitors (ICIs) represent …
carcinomas and aggressive pituitary tumors. Immune-checkpoint inhibitors (ICIs) represent …
Therapeutic targeting of the pituitary tumor microenvironment
MD Ilie, D De Alcubierre, AL Carretti… - Pharmacology & …, 2023 - Elsevier
The tumor microenvironment (TME), the complex environment in which tumors develop, has
been increasingly targeted for cancer treatment in recent years. Aggressive pituitary tumors …
been increasingly targeted for cancer treatment in recent years. Aggressive pituitary tumors …
Immunotherapy in pituitary carcinomas and aggressive pituitary tumors
After temozolomide failure, no evidence-based treatment option is currently available for
aggressive pituitary tumors (APTs) and pituitary carcinomas (PCs). Moreover, once …
aggressive pituitary tumors (APTs) and pituitary carcinomas (PCs). Moreover, once …
Tumor immune microenvironment in pituitary neuroendocrine tumors (PitNETs): increased M2 macrophage infiltration and PD-L1 expression in PIT1-lineage subset
M Luo, R Tang, H Wang - Journal of Neuro-Oncology, 2023 - Springer
Purpose Tumor immune microenvironment in pituitary neuroendocrine tumors (PitNETs) and
application of current immunotherapy for refractory PitNETs remains debated. We aim to …
application of current immunotherapy for refractory PitNETs remains debated. We aim to …
Tumour microenvironment and pituitary tumour behaviour
P Marques, M Korbonits - Journal of Endocrinological Investigation, 2023 - Springer
The pituitary tumour microenvironment encompasses a spectrum of non-tumoural cells, such
as immune, stromal or endothelial cells, as well as enzymes and signalling peptides like …
as immune, stromal or endothelial cells, as well as enzymes and signalling peptides like …
The microenvironment of pituitary adenomas: biological, clinical and therapeutical implications
The microenvironment of pituitary adenomas (PAs) includes a range of non-tumoral cells,
such as immune and stromal cells, as well as cell signaling molecules such as cytokines …
such as immune and stromal cells, as well as cell signaling molecules such as cytokines …
[HTML][HTML] Current and emerging medical therapies in pituitary tumors
N Sahakian, F Castinetti, T Brue, T Cuny - Journal of clinical medicine, 2022 - mdpi.com
Pituitary tumors (PT) represent in, the majority of cases, benign tumors for which surgical
treatment still remains, except for prolactin-secreting PT, the first-line therapeutic option …
treatment still remains, except for prolactin-secreting PT, the first-line therapeutic option …